2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 689

Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Abstract Number: 1119

Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry
Abstract Number: 348

Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Abstract Number: 1340

Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Abstract Number: 1009

PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease
Abstract Number: 1750

Pediatric Sjögren Syndrome: A Single-Center Experience
Abstract Number: 1249

Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain
Abstract Number: 2813

Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis
Abstract Number: 1720

Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome
Abstract Number: 1824

Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Abstract Number: 171

Performance of 2010 ACR/EULAR and 1987 ACR Criteria for Classification of Rheumatoid Arthritis in a Population-based Incidence Cohort, 2010-2014
Abstract Number: 2640

Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis
Abstract Number: 1373

Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
Abstract Number: 401

Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients
Abstract Number: 677

Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].